Clínic Barcelona
Institutional

Blood biomarkers: Towards a faster and more accessible diagnosis of Alzheimer’s disease

The introduction of blood biomarkers for Alzheimer’s disease is revolutionizing the biological diagnosis of this disease, enabling faster diagnosis in the early stages of the disease, for a larger number of people and in a faster, more economical and less invasive way. This is vitally important at a time when the first disease-modifying treatments for Alzheimer’s disease are about to be approved at European level.

Written By

Albert Lladó

Jefe de la Unidad de Alzheimer y otros trastornos cognitivos del Hospital Clínic Barcelona.

Alzheimer’s disease biomarkers Albert Lladó

These new treatments have been shown to slow the progression of the disease when administered in the earliest stages of Alzheimer’s disease

Related contents
Keep reading about:

Related news